Charles River Laboratories: A Well-Positioned CRO Due To Blossom In Pre-Clinical Services
- The company is a strong pick among the contract research organizations (CROs) due to a promising future in the pre-clinical services (PCS) market.
- It continues to gain share in early stage development via its PCS business, providing evidence of a nascent toxicology recovery.
- The company has reported impressive results in all the quarters for 2013, and is looking solid to continue the performance.
- More focus on strategic partnerships and mid-sized global bio-pharmaceutical firms, and increased outsourcing by the larger bio-pharmaceutical firms will help the company to better penetrate the global PCS market.